Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 24 Researches
7.7
USERS' SCORE
Moderately Good
Based on 2 Reviews
7.3
Supplement Facts
Serving Size: 3 Tablets
Amount Per Serving
%DV
Vitamin D-3 (as Cholecalciferol)
25 mcg (1,000 IU)
125%
Calcium (from Aquamin® TG Seaweed Derived Minerals and Calcium Citrate)
400 mg
31%
Magnesium (from Magnesium Oxide, Magnesium Glycinate, Magnesium Taurinate, Magnesium Citrate and Aquamin® TG Seaweed Derived Minerals)
800 mg
190%
Zinc (from L-OptiZinc® Monomethionine)
15 mg
136%
Top Medical Research Studies
8
Magnesium scaffold shows promising results
We investigated the clinical safety and performance of a new magnesium scaffold known as DREAMS 3G. This innovative treatment aims to match the effectiveness of drug-eluting stents in coronary interventions.
Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.
Overall, our findings support its potential use in heart treatments.
Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.
Overall, our findings support its potential use in heart treatments.
8
We explored how zinc affects blood clotting, particularly through a substance called Zn@SiO nanocomposite. This material shows promise as a hemostatic agent, which means it helps stop bleeding by promoting the formation of stable blood clots.
During our analysis, we examined various aspects of how this nanocomposite interacts with blood. It activates specific factors in the coagulation cascade—the process our bodies use to form clots. With the presence of zinc in the material, we observed enhanced activation of these factors, leading to improved clot formation.
Our research involved synthesizing and characterizing the Zn@SiO nanocomposite using several methods, including XRD, FTIR, and HRTEM. We also tested its effects on red blood cell aggregation, platelet adhesion, and several vital clotting time measures. The results indicate that Zn@SiO has significant hemostatic properties, showing potential for use in surgeries and trauma care.
This study highlights the exciting role of zinc in optimizing hemostasis, making it a candidate worth considering for medical applications related to bleeding management.
During our analysis, we examined various aspects of how this nanocomposite interacts with blood. It activates specific factors in the coagulation cascade—the process our bodies use to form clots. With the presence of zinc in the material, we observed enhanced activation of these factors, leading to improved clot formation.
Our research involved synthesizing and characterizing the Zn@SiO nanocomposite using several methods, including XRD, FTIR, and HRTEM. We also tested its effects on red blood cell aggregation, platelet adhesion, and several vital clotting time measures. The results indicate that Zn@SiO has significant hemostatic properties, showing potential for use in surgeries and trauma care.
This study highlights the exciting role of zinc in optimizing hemostasis, making it a candidate worth considering for medical applications related to bleeding management.
9
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
Most Useful Reviews
2
Ineffective results
After completing the cycle, my blood levels did not rise, and I experienced no beneficial effect from the supplement—essentially, it was ineffective for me.
0
No results found
I have not seen any results from using this product. In my latest blood test, my calcium levels even decreased. Therefore, I plan to stop using it and follow up with another blood test.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 24 Researches
7.7
- All Researches
9.5
We explored the effects of a newly discovered fibrinolytic enzyme from the marine fungus Penicillium steckii KU1, particularly its interaction with zinc in the context of blood clot dissolution. This enzyme, which has a molecular weight of 12.6 kDa, is a plasmin-like protein that becomes more active in the presence of zinc. While it effectively dissolves blood clots, achieving complete dissolution in just 30 minutes with a specific concentration, we also observed that its activity is significantly inhibited by certain agents like EDTA.
Interestingly, the enzyme demonstrated a low level of hemolysis at just 2.60%, indicating that it could be a safer alternative for thrombolytic therapy. However, it's important to note that while zinc enhances the enzymatic activity, the isolated effects of zinc on blood clot breakdown remain somewhat unclear due to the enzyme's overall presence.
This research highlights the potential of the marine-derived enzyme and the role of zinc, suggesting that further studies could provide deeper insights into improving thrombolytic treatments. These findings could be significant for enhancing the safety and effectiveness of therapies designed for clot management.
Interestingly, the enzyme demonstrated a low level of hemolysis at just 2.60%, indicating that it could be a safer alternative for thrombolytic therapy. However, it's important to note that while zinc enhances the enzymatic activity, the isolated effects of zinc on blood clot breakdown remain somewhat unclear due to the enzyme's overall presence.
This research highlights the potential of the marine-derived enzyme and the role of zinc, suggesting that further studies could provide deeper insights into improving thrombolytic treatments. These findings could be significant for enhancing the safety and effectiveness of therapies designed for clot management.
9.5
We investigated how a new hemostatic agent, HEMO-IONIC®, which is enriched with zinc and made from calcium alginate, influences blood clotting and tissue repair. Our focus was on how this innovative compress can help control bleeding while also promoting healing after surgery.
In our study, we compared the effects of HEMO-IONIC with other common hemostatic products, like Surgicel® and TachoSil®. What we found was impressive: HEMO-IONIC not only effectively helped to achieve hemostasis, but it also supported the health of vascular endothelial cells, which are crucial for tissue repair.
Unlike Surgicel, which showed high cytotoxicity, and TachoSil, which inhibited cell migration, HEMO-IONIC promoted the migration of endothelial cells and increased angiogenesis—the formation of new blood vessels. This means that it not only helps stop bleeding but also enhances the body's natural repair processes by attracting essential healing cells and speeding up the maturation of the extracellular matrix.
Overall, we found that using HEMO-IONIC at the end of surgical procedures has long-term positive effects on every phase of tissue repair, making it a promising alternative to traditional hemostatic agents.
In our study, we compared the effects of HEMO-IONIC with other common hemostatic products, like Surgicel® and TachoSil®. What we found was impressive: HEMO-IONIC not only effectively helped to achieve hemostasis, but it also supported the health of vascular endothelial cells, which are crucial for tissue repair.
Unlike Surgicel, which showed high cytotoxicity, and TachoSil, which inhibited cell migration, HEMO-IONIC promoted the migration of endothelial cells and increased angiogenesis—the formation of new blood vessels. This means that it not only helps stop bleeding but also enhances the body's natural repair processes by attracting essential healing cells and speeding up the maturation of the extracellular matrix.
Overall, we found that using HEMO-IONIC at the end of surgical procedures has long-term positive effects on every phase of tissue repair, making it a promising alternative to traditional hemostatic agents.
9
We explored the role of calcium in promoting blood coagulation using a new zeolite-embedded regenerated cellulose aerogel (Z-RCA). This innovative hemostatic agent was designed to minimize common issues seen with previous zeolite-based products, like heat-induced tissue damage and unwanted blood clotting elsewhere in the body.
Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.
In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.
In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
9
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
8
We explored the impact of different calcium infusions on clotting risks in neonates undergoing cardiac surgery. Our study involved analyzing data from 135 babies who received either calcium chloride or calcium gluconate during their treatment.
The findings highlighted a significant concern: when using calcium chloride, the incidence of thrombotic events was notably higher compared to those treated with calcium gluconate. Specifically, the odds of experiencing a blood clot were over three times greater in patients given calcium chloride.
With an overall thrombus occurrence of 9.9%, we observed that only 4.6% of the group receiving calcium gluconate developed such complications compared to 15% in the calcium chloride group. The evidence suggests that switching from calcium chloride to calcium gluconate could potentially reduce the risk of harmful blood clots in these vulnerable patients.
The findings highlighted a significant concern: when using calcium chloride, the incidence of thrombotic events was notably higher compared to those treated with calcium gluconate. Specifically, the odds of experiencing a blood clot were over three times greater in patients given calcium chloride.
With an overall thrombus occurrence of 9.9%, we observed that only 4.6% of the group receiving calcium gluconate developed such complications compared to 15% in the calcium chloride group. The evidence suggests that switching from calcium chloride to calcium gluconate could potentially reduce the risk of harmful blood clots in these vulnerable patients.
User Reviews
USERS' SCORE
Moderately Good
Based on 2 Reviews
7.3
- All Reviews
- Positive Reviews
- Negative Reviews
2
Ineffective results
After completing the cycle, my blood levels did not rise, and I experienced no beneficial effect from the supplement—essentially, it was ineffective for me.
0
No results found
I have not seen any results from using this product. In my latest blood test, my calcium levels even decreased. Therefore, I plan to stop using it and follow up with another blood test.
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Jin Z, Chen L, Liu X, Xia R, Li W, et al. Zeolite firmly anchored regenerated cellulose aerogel for efficient and biosafe hemostasis. Int J Biol Macromol. 2025;304:140743. doi:10.1016/j.ijbiomac.2025.140743
- Tran VA, Griffin EM, Elliott JD, Scholl RL, Hill RB, et al. Thrombotic Complications Associated With Right Atrial Lines in Neonates and Infants Undergoing Cardiac Surgery. Is Calcium Chloride a Culprit?. J Cardiothorac Vasc Anesth. 2025. doi:10.1053/j.jvca.2025.01.008
- Kim J, Kim M, Lee CS, Choi EY. Sufficient Magnesium Intake Reduces Retinal Vein Occlusion Risk: National Health and Nutrition Examination Survey Analysis. Nutrients. 2025;17. doi:10.3390/nu17071285
- Guo X, Zeng X, He Y, Zhang X, Shi W, et al. An Antibacterial, Antioxidant Adherent Sponge Constructed for Control of Arterial Bleeding Via Gallic Acid-Mediated Robust Assembly of Fibrous Clay in Collagen. ACS Appl Mater Interfaces. 2025;17:16489. doi:10.1021/acsami.4c19209
- Müller M, Ludwig L, Englert H, Riedl KA, Müller MC, et al. A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffolds. Sci Rep. 2024;14:26691. doi:10.1038/s41598-024-77266-0
- Zhang J, Chen Z, Rao L, He Y. Coronary bioresorbable metallic stents: Advancements and future perspectives. J Cardiol. 2025;85:69. doi:10.1016/j.jjcc.2024.08.003
- Włodarczak A, Rola P, Włodarczak S, Szudrowicz M, Giniewicz K, et al. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions. J Pers Med. 2024;14. doi:10.3390/jpm14050540
- Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, et al. Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry. Cardiovasc Revasc Med. 2023;57:53. doi:10.1016/j.carrev.2023.06.022
- Włodarczak A, Rola P, Barycki M, Furtan Ł, Łanocha M, et al. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort. Diab Vasc Dis Res. 2023;20:14791641231188705. doi:10.1177/14791641231188705
- Gotru SK, Mammadova-Bach E, Sogkas G, Schuhmann MK, Schmitt K, et al. MAGT1 Deficiency Dysregulates Platelet Cation Homeostasis and Accelerates Arterial Thrombosis and Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol. 2023;43:1494. doi:10.1161/ATVBAHA.122.318115
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study. EuroIntervention. 2023;19:e414. doi:10.4244/EIJ-D-23-00326
- Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Starmer G, et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention. 2023;19:232. doi:10.4244/EIJ-D-22-01069
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023;59:101940. doi:10.1016/j.eclinm.2023.101940
- Pompei G, Campo G, Ruggiero R, Maffeo D, Sgura F, et al. Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. Int J Cardiol. 2023;383:1. doi:10.1016/j.ijcard.2023.04.029
- Fedele G, Castiglioni S, Maier JAM, Locatelli L. The Effects of Sirolimus and Magnesium on Primary Human Coronary Endothelial Cells: An In Vitro Study. Int J Mol Sci. 2023;24. doi:10.3390/ijms24032930
- Tonai K, Katayama S, Koyama K, Sata N, Tomioka Y, et al. Association between hypomagnesemia and coagulopathy in sepsis: a retrospective observational study. BMC Anesthesiol. 2022;22:359. doi:10.1186/s12871-022-01903-2
- Seguchi M, Aytekin A, Lenz T, Nicol P, Alvarez-Covarrubias HA, et al. Challenges of the newer generation of resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation. J Cardiol. 2023;81:179. doi:10.1016/j.jjcc.2022.09.003
- Venkatappa MM, Udagani C, Hanumegowda SM, Pramod SN, Venkataramaiah S, et al. Effect of Biofunctional Green Synthesized MgO-Nanoparticles on Oxidative-Stress-Induced Tissue Damage and Thrombosis. Molecules. 2022;27. doi:10.3390/molecules27165162
- Kunhiraman S, Haridas M, Basheer SM, Chellappan S, Abdulhameed S. Least hemolytic, 12.6 kDa, plasmin-like fibrinolytic protease from marine Penicillium steckii KU1. Int J Biol Macromol. 2024;283:137854. doi:10.1016/j.ijbiomac.2024.137854
- M S M, Samal DB, Amirtraj J V, Subramanian S, Venkatasubbu GD. Enhanced coagulation cascade activation and styptic effects of Zn@SiO nanocomposite. Colloids Surf B Biointerfaces. 2024;239:113927. doi:10.1016/j.colsurfb.2024.113927
- Coupland CA, Naylor-Adamson L, Booth Z, Price TW, Gil HM, et al. Platelet zinc status regulates prostaglandin-induced signaling, altering thrombus formation. J Thromb Haemost. 2023;21:2545. doi:10.1016/j.jtha.2023.05.008
- Liao X, Ji P, Chi K, Chen X, Zhou Y, et al. Enhanced inhibition of protein disulfide isomerase and anti-thrombotic activity of a rutin derivative: rutin:Zn complex. RSC Adv. 2023;13:11464. doi:10.1039/d3ra01135f
- Ponsen AC, Proust R, Soave S, Mercier-Nomé F, Garcin I, et al. A new hemostatic agent composed of Zn-enriched Ca alginate activates vascular endothelial cells and promotes tissue repair . Bioact Mater. 2022;18:368. doi:10.1016/j.bioactmat.2022.01.049
- Yu X, Wang Z, Li YV. Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study. J Thromb Thrombolysis. 2022;53:291. doi:10.1007/s11239-021-02600-6
